Table 6 Cost-effectiveness analysis of benralizumab treatment based on severe exacerbations
From: Real-life cost-effectiveness of benralizumab in patients with severe asthma
Mean (SD) per patient | Previous 12 months (baseline) | At 12 months on benralizumab |
|---|---|---|
No. of exacerbations | 5.50 (2.63) | 0.66 (0.94) |
Direct healthcare costs (in €) | 10,292 (7885) | 13,204 (2145) |
Difference in | ||
% reduction of exacerbations | 88.14 | |
Costs (€) | 2912 | |
Total cost to reduce 1 exacerbation (€) | 602 | |
p value | < 0.001 | |
Cost-effectiveness ratio | 3304 | |
Cohen’s d | 2.00 (1.49–2.51) | |